Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer-Reference-Cited by-同舟云学术

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer

Published:2017-06-01 Issue:6 Volume:3 Page:793
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Joensuu Heikki¹,Kellokumpu-Lehtinen Pirkko-Liisa²,Huovinen Riikka³,Jukkola-Vuorinen Arja⁴,Tanner Minna²,Kokko Riitta⁵,Ahlgren Johan⁶,Auvinen Päivi⁷,Lahdenperä Outi³,Kosonen Sanna⁸,Villman Kenneth⁹,Nyandoto Paul¹⁰,Nilsson Greger¹¹,Poikonen-Saksela Paula¹,Kataja Vesa¹²,Junnila Jouni¹³,Bono Petri¹,Lindman Henrik¹¹

Affiliation:

1. Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

2. Department of Oncology, Tampere University Hospital and University of Tampere, Tampere, Finland

3. Department of Oncology, Turku University Central Hospital, Turku, Finland

4. Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland

5. Kanta-Häme Central Hospital, Hämeenlinna, Finland

6. Gävle Hospital, Gävle, Sweden

7. Cancer Center, Kuopio University Hospital, Kuopio, Finland

8. Kotka Central Hospital, Kotka, Finland

9. Örebro University Hospital, Örebro, Sweden

10. Päijät-Häme Central Hospital, Lahti, Finland

11. Uppsala University Hospital, Uppsala, Sweden

12. Cancer Center, Kuopio University Hospital, Kuopio, Finland12Vaasa Central Hospital, Vaasa, Finland

13. 4Pharma, Turku, Finland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study;Frontiers in Endocrinology;2024-03-19

2. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study;Expert Opinion on Pharmacotherapy;2024-03-03

3. Macrophages Promote Subtype Conversion and Endocrine Resistance in Breast Cancer;Cancers;2024-02-05

4. Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications;Critical Reviews™ in Therapeutic Drug Carrier Systems;2024

5. The effect of radiotherapy on patients with pathological stage IIB breast cancer after breast-conserving surgery or mastectomy: A cohort study;Journal of the Chinese Medical Association;2023-12-12